Alzamend Neuro Inc

NASDAQ: ALZN · Healthcare · Biotechnology

PublicHQ Atlanta, GA · FultonCIK 0001677077Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 35DQ —GM —SS 25

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$4.5M

Employees

Market cap

$3.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$4.5M-$4.5M2025

Operating income-$4.5M-$4.5M2025

Total assets$4.6M$4.6M2025

Liabilities$634.8k$634.8k2025

Equity$4.0M$4.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Alzamend Neuro Inc earned -$4.5M in FY2025 net income.

Peers · Healthcare

BioRestorative Therapies, Inc.38D Cann American Corp.——Matinas BioPharma Holdings, Inc.32D NuGen Medical Devices Inc.24D

Neighbors

Fulton →

The Coca-Cola Company$47.9B82B+The Home Depot, Inc.$164.7B82B+The Southern Company$28.9B72B United Parcel Service, Inc.$88.7B71B Intercontinental Exchange, Inc.$12.6B76B+Norfolk Southern Corporation$12.2B81B+

Key facts

CEOStephan Jackman

SectorHealthcare

IndustryBiotechnology

HeadquartersAtlanta, GA

ExchangeNASDAQ: ALZN

Employees5

IPO date2021-06-15

Latest filings

8-K2026-04-17 8-K2026-03-20 10-Q2026-03-11 8-K2026-03-06 DEF 14A2026-02-26 10-Q2025-12-09 8-K2025-11-18 8-K2025-10-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.